Clinical responsiveness to gefitinib and erlotinib in NSCLC have been shown to correlate with somatic mutations in the EGFR gene, which result in increased sensitivity to inhibition of growth by the drugs [8,10-12]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.